MYELOMA CANADA RESEARCH GRANT
The Myeloma Canada Research Grant is made possible through generous donations from myeloma patients, their family members, caregivers and other private individuals who support us in our mission of making myeloma matter.
Myeloma Canada is the only national organization uniquely devoted to the Canadian myeloma community. As a patient-‐driven, patient-‐focused organization, our goal is to improve patient outcomes through education, awareness, advocacy and research.
The Myeloma Canada Research Grant, made possible through donations from private individuals, will be presented annually to a Canadian researcher whose submission best meets the criteria set forth in this document as determined by a Peer Review Committee.
This year's award will be in the amount of $50,000. No funds will be provided for institutional overhead costs.
Proposals for research project funding must be directly related to myeloma and aligned to our objective of improving patient outcomes within two to three years. As such, priority will be given to the submission deemed to have the greatest probability of positively impacting clinical practice within the defined time frame. The focus will be on proposals that contribute to the advancement of clinical practice through translational or clinical research. If, in the opinion of the Peer Review Committee, no submission meets the criteria, the grant will not be awarded in 2013 and the grant amount will be carried forward to 2014.
Statement of Principles for Research Investment
These principles underpin our decisions on research strategy and investment.
We aim to ensure that our investment in research adds the greatest possible value to overall research activity in the field of myeloma. We will support work that is directly relevant to our strategic objectives, and will bring the most value to the myeloma community.
We will always seek to use our funds efficiently, providing value for money in the research that we support and communicating, in appropriate ways, the processes and outcomes of the research we fund.
• Peer reviewed
We will ensure effective, independent peer review of all research applications considered, enabling us to invest in the highest quality research.
While recognizing the need for researchers to protect appropriately their research interests, we will aim to ensure that researchers funded by us are as open as possible in discussing their work with other researchers and, in accessible forms, with the public.
• With integrity
We demand integrity of all involved in decisions on grant awards and by the researchers and research institutions who are recipients of our grants. We expect all actual or potential conflicts of interest to be declared and we will establish appropriate mechanisms to ensure this.
We expect all research activity funded by us to be carried out to the highest standards of current ethical and research practice.
In turn, the Peer Review Committee, composed of members of the Myeloma Canada Scientific Advisory Board, review and evaluate each application based on its merits in light of the established selection criteria.
This year's Myeloma Canada Research Grant is awarded to Dr Suzanne Trudel
After having reviewed and evaluated each submission, the Peer Review Commitee is pleased to announce that the recipient of the third annual Myeloma Canada Research Grant in the amount of $50,000 is Dr. Suzanne Trudel of the Princess Margaret Cancer Centre in Toronto.
Dr. Trudel’s project involves the identification of predictive markers of response and mechanisms of resistance to MEK inhibitors in myeloma tumours.
Click here to read more on Dr Suzanne Trudel and her contribution towards finding a cure against multiple myeloma.
Myeloma Canada is affiliated with the International Myeloma Foundation, the world's oldest and largest myeloma organization
Myeloma Canada gratefully acknowledges the generous unrestricted educational grants from our website sponsors: